<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407381</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00005254</org_study_id>
    <nct_id>NCT00407381</nct_id>
  </id_info>
  <brief_title>The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study</brief_title>
  <official_title>Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if the investigational drug Ranibizumab (RBZ) given by
      injection into the eye, is safe and effective to use in people with diabetic macular edema
      (DME). The investigators want to compare RBZ to laser treatment which is the current standard
      way to treat DME.

      RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood
      vessels that cause loss of vision in patients with DME.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The READ-2 Study is a phase 2 randomized, multi-center clinical trial to be conducted under
      an investigator-initiated investigational new drug (IND). The study aims to enroll 126
      patients, who will be randomized into 3 different groups. The primary objectives of the
      READ-2 Study are: (a) to obtain data on the bioactivity and dose interval effects of
      intravitreal ranibizumab (RBZ) alone, as well as in combination with laser photocoagulation,
      on retinal thickness and visual acuity in subjects with DME; and (b) to obtain additional
      safety and bioactivity data to aid in the design of a phase 3 clinical trial to evaluate
      ranibizumab as a therapeutic option for patients with DME The study consists of a 2-week
      screening period (Days -14 to 0), a 6-month treatment period with a primary time endpoint,
      and a 18-month follow-up and treatment period with secondary time endpoints. Consented
      subjects will enter the 14-day screening period to determine eligibility. Serum chemistry and
      hematology testing, urinalysis, pregnancy testing, and macular thickness measurements based
      on optical coherence tomography (OCT) will be performed. Screening will also include VA,
      ophthalmic examination and fluorescein angiography (FA) entry criteria.

      Patients who have ETDRS visual acuity of 20/40 or worse, but better than or equal to 20/320
      due to foveal thickening from macular edema secondary to diabetes (type 1 or 2) and who meet
      eligibility criteria will be eligible to enroll in the study. Baseline foveal thickness by
      OCT must be at least 250, which is often associated with VA of 20/40 or worse and which
      provides sufficient thickening so that a treatment effect is easily detectable (Nguyen et al.
      2004). Approximately 126 patients with DME will be enrolled in this study from all clinical
      sites in the study. Every effort will be made to recruit and enroll eligible patients from
      men and women of all ethnic and social backgrounds. Patients who meet entry criteria will be
      able to enroll in the study until the quota of patients has been achieved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change of best corrected visual acuity letters (BCVA) at month 6</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab (RBZ) intravitreal injection alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser photocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser with Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser following intravitreal injection of RBZ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_label>Laser with Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <description>Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_label>Laser with Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Signed informed consent and authorization of use and disclosure of protected health
             information

          -  Age greater than 18 years

          -  Diagnosis of diabetes mellitus (type 1 or type 2) and serum HbA1c greater than 5.5%
             within 12 months of randomization

          -  Retinal thickening secondary to diabetes mellitus (diabetic macular edema) involving
             the center of the fovea.

          -  Diagnosis must be confirmed by OCT images

          -  Foveal thickness of greater than 250, as assessed by OCT

          -  Best corrected visual acuity score in the study eye of 20/40 to 20/320 inclusive
             (Snellen equivalents using the ETDRS protocol at a distance of 4 meters). Only one eye
             will be treated in the study. If both eyes are eligible, the investigator will select
             the eye to be enrolled. Visual acuity in the non-study eye must be greater than
             20/800.

          -  In the opinion of the investigator, decreased vision in the study eye is due to foveal
             thickening from DME and not from other obvious causes.

          -  In the opinion of the investigator, laser photocoagulation can be withheld for at
             least 30 days after the patient has enrolled in the study

        Exclusion Criteria:

          -  Panretinal photocoagulation or macular photocoagulation within 3 months of study entry
             in the study eye

          -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,
             triamcinolone) within 3 months of study entry

          -  Previous participation in a study and receipt of anti-angiogenic drugs (pegaptanib
             sodium, ranibizumab, anecortave acetate, protein kinase C inhibitor, etc.) within 2
             months of study entry

          -  Eyes in which the investigators do not feel appropriate to do any additional laser
             photocoagulation

          -  Proliferative diabetic retinopathy in the study eye, with the exceptions of inactive,
             fibrotic proliferative diabetic retinopathy that has regressed following pan-retinal
             laser photocoagulation or tufts of neovascularization elsewhere (NVE) less than one
             disc area with no vitreous hemorrhage

          -  Vitreomacular traction or epiretinal membrane in the study eye evident
             biomicroscopically or by OCT

          -  Structural damage to the center of the macula in the study eye likely to preclude
             improvement in visual acuity following the resolution of macular edema, including
             atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), macular
             ischemia, or organized hard exudate plaque

          -  Ocular disorders in the study eye that may confound interpretation of study results,
             including retinal vascular occlusion, retinal detachment, macular hole, or choroidal
             neovascularization of any cause (e.g., age related macular degeneration (AMD), ocular
             histoplasmosis, or pathologic myopia)

          -  Concurrent disease in the study eye that could compromise visual acuity or require
             medical or surgical intervention during the first 6-month study period

          -  Eyes which are likely to need cataract surgery and intraocular lens implantation
             within the first 6 months of the study

          -  Cataract surgery in the study eye within 3 months of study entry;
             Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 2 months of study entry; or any
             other intraocular surgery within 3 months preceding Day 0.

          -  History of vitreoretinal surgery in the study eye within 3 months of study entry

          -  Uncontrolled glaucoma (defined as intraocular pressure greater than 30 mm Hg despite
             treatment with anti-glaucoma medications)

          -  Uncontrolled diabetes mellitus, as evidenced by glycosylated hemoglobin (HbA1c) value
             greater than 12%

          -  Premenopausal women not using adequate contraception

          -  Any women who are pregnant

          -  International normalized ratio (INR) greater than or equal to 3.0 (e.g. due to current
             treatment with warfarin). The use of aspirin or other anticoagulants is not an
             exclusion

          -  History of gastrointestinal bleeding within 2 months of study enrollment

          -  History of major gastrointestinal, cardiothoracic, gynecological, genitourinary, or
             orthopedic surgeries within 2 months of study enrollment

          -  History of cerebral vascular accident, myocardial infarction, transient ischemic
             attacks within 6 months of study enrollment

          -  Any patients who are on renal dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Do, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Truhlsen Eye Institute, University of Nebraska Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Retina Consultants</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Eye Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants, PC</name>
      <address>
        <city>West Springfield</city>
        <state>Massachusetts</state>
        <zip>01089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists, PC</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern New England Retina Associates</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <results_first_submitted>August 30, 2016</results_first_submitted>
  <results_first_submitted_qc>March 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab Only</title>
          <description>Ranibizumab (RBZ) intravitreal injection alone
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.</description>
        </group>
        <group group_id="P2">
          <title>Laser Only</title>
          <description>Laser photocoagulation
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
        <group group_id="P3">
          <title>Laser With Ranibizumab (RBZ)</title>
          <description>Laser following intravitreal injection of RBZ
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab Only</title>
          <description>RBZ intravitreal injection alone
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.</description>
        </group>
        <group group_id="B2">
          <title>Laser Only</title>
          <description>Laser photocoagulation
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
        <group group_id="B3">
          <title>Laser With RBZ</title>
          <description>Laser following intravitreal injection of RBZ
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="32" upper_limit="84"/>
                    <measurement group_id="B2" value="62" lower_limit="34" upper_limit="86"/>
                    <measurement group_id="B3" value="62" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="B4" value="62" lower_limit="32" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6</title>
        <description>Mean change of best corrected visual acuity letters (BCVA) at month 6</description>
        <time_frame>6 months</time_frame>
        <population>Mean change in BCVA at month 6</population>
        <group_list>
          <group group_id="O1">
            <title>RBZ Alone</title>
            <description>RBZ intravitreal injection alone
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.</description>
          </group>
          <group group_id="O2">
            <title>Laser Alone</title>
            <description>Laser photocoagulation
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
          </group>
          <group group_id="O3">
            <title>Laser With RBZ</title>
            <description>Laser following intravitreal injection of RBZ
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6</title>
          <description>Mean change of best corrected visual acuity letters (BCVA) at month 6</description>
          <population>Mean change in BCVA at month 6</population>
          <units>Mean letter change in BCVA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="5.54"/>
                    <measurement group_id="O2" value="-0.43" spread="4.56"/>
                    <measurement group_id="O3" value="3.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab Only</title>
          <description>RBZ intravitreal injection alone
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.</description>
        </group>
        <group group_id="E2">
          <title>Laser Only</title>
          <description>Laser photocoagulation
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
        <group group_id="E3">
          <title>Laser With Ranibizumab</title>
          <description>Laser following intravitreal injection of RBZ
Ranibizumab: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and PRN with dosing criteria.
Laser photocoagulation: Laser photocoagulation in either focal or grid pattern as determined by investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous Hemorrhages</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quan Dong Nguyen, MD, MSc</name_or_title>
      <organization>University of Nebraska</organization>
      <phone>4025591855</phone>
      <email>quan.nguyen@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

